Hence the subdued numbers put out by analysts who know the score but are CTA until the first approval is secured. Once the first approval is done, the additional applications usually aren't quite the same level of PIA. There is competition in the rheumatoid arthritis space. Gilead just had an NDA put on hold, requesting more information, but it was approved in Europe and Japan.